Kalaris Reports Loss Cash at 88 Million
Kalaris Therapeutics (NASDAQ:KLRS), a clinical-stage biopharmaceutical company focused on treatments for retinal diseases, posted its second quarter 2025 earnings on August 13, 2025. The headline result was a GAAP loss per share of $0.61. As anticipated, the company did not report any revenue, aligning with its pre-commercial stage. While operating expenses rose sharply due to clinical trial activity and public company costs, Cash and cash equivalents stood at $88.4 million (GAAP) as of June 30, 2025, following the recent merger, substantially increasing its financial runway. Overall, the quarter underscored both the investment-heavy nature of early-stage biotech and the importance of upcoming clinical milestones.
Source: Analyst estimates for the quarter provided by FactSet.
Kalaris Therapeutics is dedicated to developing novel treatments for serious retinal diseases. Its most advanced product candidate is TH103, a protein-based agent designed to block abnormal blood vessel growth in the eye.
Source Fool.com
